CDSCO bars cosmetic injectables, squeezing India's aesthetic clinic chains
India's drug regulator CDSCO issued a May 18 advisory prohibiting cosmetics from being administered as injections, directly targeting aesthetic clinics offering GLP-1, glutathione, collagen and hyaluronic acid jabs. The move threatens revenue streams for Indian beauty boutiques and aesthetic retail chains that have built service menus around injectable treatments.
What happened
India's drug regulator CDSCO issued a May 18 advisory barring cosmetics from being administered as injections, targeting aesthetic clinics offering GLP-1,
Why this matters
Distressed valuations are coming for India's injectable-heavy aesthetic chains—scout roll-up targets with strong topical/device portfolios that can absorb dislocated clinics at a discount.